Weight Management of Dialysis Patients

qinxiu zhang

Status: Not yet enrolling

Conditions: Hypertension; Hemodialysis; Life Quality; Cardiovascular Events; Interdialytic Weight Gain; Dry Weight

Treatments: Other: Family weight self-measurement and remote follow-up management based on wechat.; Other: Routine care

Study type: Interventional

Funder types: Other

Identifiers

NCT06333574

CDUTCM20240313

Details and patient eligibility

About

The goal of this clinical trial is to Improve the quality of life in Hemodialysis patient. The main questions it aims to answer are:

• [Improve the self-compliance of dialysis patients with weight management]
• [alleviate the volume load of dialysis patients and reduce cardiovascular complications] Participants will be divided into two groups based on a weight management regimen： Control group: received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.

Intervention group: On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.

Enrollment: 100 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18;
• Dialysis age ≥3 months;
• Survival ≥12 months;
• Patients themselves or family members can use wechat;
• Informed consent

Exclusion criteria

• Have a cognitive or intellectual disability unable to read and understand SMS;
• Have mental illness;
• Other serious complications occurred

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Control group

Other group

Description:

received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.

Treatment:

Other: Routine care

Intervention group

Other group

Description:

On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.

Treatment:

Other: Family weight self-measurement and remote follow-up management based on wechat.